| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CORRESPONDENCE: B.J. Currie, Menzies School of Health Research and Northern Territory Clinical School, Flinders University, Darwin, Australia. Fax: 61 889275187. E-mail: bart@menzies.edu.au
Keywords: Burkholderia pseudomallei, cystic fibrosis, epidemiology, melioidosis, pneumonia, septic shock
Received: January 30, 2003
Accepted April 25, 2003
Abstract
Melioidosis is endemic in South East Asia, Asia and northern Australia. Infection usually follows percutaneous inoculation or inhalation of the causative bacterium, Burkholderia pseudomallei, which is present in soil and surface water in the endemic region. While 20–36% of melioidosis cases have no evident predisposing risk factor, the vast majority of fatal cases have an identified risk factor, the most important of which are diabetes, alcoholism and chronic renal disease.
Half of all cases present with pneumonia, but there is great clinical diversity, from localised skin ulcers or abscesses without systemic illness to fulminant septic shock with multiple abscesses in the lungs, liver, spleen and kidneys. At least 10% of cases present with a chronic respiratory illness (sick >2 months) mimicking tuberculosis and often with upper lobe infiltrates and/or cavities on chest radiography. As with tuberculosis, latency with reactivation decades after infection can also occur, although this is rare.
Confirmation of diagnosis is by culture of B. pseudomallei from blood, sputum, throat swab or other samples. Microbiology laboratories need to be informed of the possibility of melioidosis, as those not familiar with it can misidentify the organism. Antibiotic therapy is initial intensive therapy with i.v. ceftazidime or meropenem or imipenem +/– cotrimoxazole for
Melioidosis has been increasingly recognised in returning travellers in Europe and recently melioidosis and colonisation with B. pseudomallei have been documented in cystic fibrosis patients visiting or resident in endemic areas.
10 days, followed by eradication therapy with cotrimoxazole +/– doxycycline +/– chloramphenicol (first 4 weeks only) for 3 months.
In Rangoon, Burma, in 1912, Whitmore and Krishnaswami 1 described cases of a newly recognised septicaemic disease. Some fatal cases were morphia addicts and autopsy findings were characterised by widespread caseous consolidation of the lungs, classically with abscesses in the liver, spleen, kidney and subcutaneous tissues. This is the fulminant end of the spectrum of a disease now recognised as a major cause of fatal septicaemia in endemic tropical locations. The Gram-negative bacillus isolated from the lungs and other organs was similar to that causing glanders (Burkholderia mallei), but was motile. Whitmore 2 also noted the clinical resemblence to glanders. The disease was named melioidosis by Stanton and Fletcher 3, based on a derivation of the Greek melis (distemper of asses). After various earlier names, the causative bacterium was called Pseudomonas pseudomallei 4. Due to 16s ribosomal ribonucleic acid sequences, deoxyribonucleic acid (DNA)-DNA homology values, the cellular lipid and fatty acid composition, and phenotypic characteristics within the Pseudomonas genus, seven species were moved to a new genus, Burkholderia 5, in 1992. The new genus was named after the US microbiologist Walter Burkholder, who, in 1949, first described B. cepacia, formerly P. cepacia, as the plant pathogen causing bacterial rot of onions ("slippery skin") 6. B. cepacia is the type species in the genus, which includes the organisms causing melioidosis (B. pseudomallei) and glanders (B. mallei). A number of additional related environmental bacterial species have subsequently been discovered and added to the Burkholderia genus.
Burkholderia pseudomallei in soil and water
Although originally considered a zoonotic infection from rodents 7, zoonotic infection is actually very rare, with only three possible cases described from Australia 8. It is now clear that humans and animals are infected by exposure to B.pseudomallei present in soil and surface water in endemic locations 9.
The interaction of B. cepacia and other species in the Burkholderia genus with environmental elements has relevance for B. pseudomallei 10. B. cepacia strains have an ecological niche in the rhizosphere of plants and there is great interest from the agricultural industry in using B. cepacia as a biological control agent 11. B. cepacia can degrade some toxic compounds in pesticides and herbicides, and can kill many soil-borne plant pathogens. However, rapid mutation and adaptation is considered likely, given the presence of numerous insertion sequences within B. cepacia 11, including, for some strains, sequences identical to B. pseudomallei insertion sequences 12. This justifies concern that widespread agricultural use of B. cepacia may be a hazard to human health and, most particularly, for patients with cystic fibrosis (CF) 11. Recent molecular studies have confirmed, for the first time, that as with B. pseudomallei, human pathogenetic strains of B. cepacia from CF patients can be found in local agricultural soils 13.
Endemic melioidosis
Following the initial account in Burma, melioidosis was documented in humans and animals in Malaysia and Singapore from 1913 7 and then in Vietnam from 1925 and Indonesia from 1929 14, 15. The majority of cases of melioidosis are from South East Asia and northern Australia.
Thailand has reported the greatest numbers 16–18, with an estimated 2,000–3,000 cases of melioidosis each year 19. Melioidosis is also common in Malaysia 20–22 and Singapore 23–28. Other countries in the region where melioidosis is recognised in humans and animals include China (especially Hong Kong), Taiwan and Brunei 15, 29–33. Melioidosis is also likely to occur in Cambodia, Laos and the Philippines 15, 19, 34. Melioidosis has been increasingly recognised in India 29, 35, 36, although reports that some of the "plague" scares of 1994 may have been cases of melioidosis 37 have been disproved 38, 39. Cases have been reported from Sri Lanka, Bangladesh and Pakistan 15, 40. A recent study from southern Vietnam confirmed that melioidosis is present but far less common than in north-east Thailand 41. Cases of melioidosis have also been documented in Papua New Guinea 42 and Fiji, but the extent of endemicity in the Pacific islands remains to be defined.
The two locations where melioidosis is arguably the most important single bacterial pathogen for humans are some north-east provinces in Thailand and the top end of the Northern Territory of Australia. In north-east Thailand, 20% of community-acquired septicaemic cases are due to melioidosis, which accounts for 39% of fatal septicaemias 17 and 36% of fatal community-acquired pneumonias 43. At the Royal Darwin Hospital in the Northern Territory, melioidosis is the most common cause of fatal community-acquired bacteraemic pneumonia 44. Within Thailand, melioidosis occurs in other northern provinces and to a lesser extent in the south, and it is also well recognised in other regions in tropical northern Australia, such as northern Queensland 45–47 and the Kimberley region of northern Western Australia 48.
Global warming may well result in expansion of the endemic boundaries of melioidosis. In Australia it is predicted that temperature, overall rainfall and rainfall intensities will all increase in northern regions, possibly facilitating a southern extension of melioidosis 49.
Melioidosis introduced into nontropical regions
In addition to endemic melioidosis, there are several documented situations where melioidosis has become established in nontropical locations. In France, in the 1970s, cases of melioidosis occurred in animals in a Paris zoo and then spread to other zoos and equestrian clubs in France 15. As well as fatal animal and human cases, there was extensive soil contamination persisting for some years. B. pseudomallei was considered likely to have been introduced by importation of infected animals, possibly a panda donated to France by Mao-Tse-Tung or horses from Iran 15. A cluster of cases occurred over a 25-yr period in south-west Western Australia (31°S), involving animal cases and one human infection in a farmer 50. Ribotyping of the farm animal and human isolates and one isolate from the soil showed identical patterns 51. This supports the suggestion of clonal introduction of B.pseudomallei into this temperate region, probably via an infected animal, with environmental contamination, local dissemination and persistence over 25 yrs.
Melioidosis in travellers to and returned from endemic regions
Melioidosis was an important cause of morbidity and mortality in foreign troops fighting in South East Asia. Dance 15 noted that 100 cases occurred among French forces in Indochina between 1948–1954, and by 1973, 343 cases had been reported in American troops fighting in Vietnam 52. Concerns of re-activation of latent infection in soldiers returned from Vietnam, with estimates from serology studies of 
225,000 potential cases, resulted in melioidosis being called the "Vietnamese time bomb" 53, 54. However, while occasional cases of re-activation of B. pseudomallei still occur in Vietnam veterans 55, 56, it is rare in comparison to the numbers exposed.
Melioidosis remains a risk for travellers to endemic areas, especially if they have a recognised risk factor as discussed below. Adventure tours resulting in extensive exposure to wet season soils and surface water are a possible scenario for infection. This occurred in early 2002 in a young French tourist who died from fulminant melioidosis septicemic pneumonia after exposure to muddy soils on a camping tour of a tropical Australian wilderness park. Imported melioidosis cases are seen each year in hospitals in southern Australia 44. Some of these cases are acquired in tourists returning from northern Australia and others are acquired in South East Asia. Occasional imported cases are also reported from Europe and the USA 40, 57, 58. While the vast majority of these cases are from recent acquisition of B. pseudomallei, asoccurs with >90% of cases in northern Australia 59, occasional patients may have chronic melioidosis or have re-activation of disease from a latent focus many years after leaving an endemic area, as noted above in returned soldiers from Vietnam.
With increasing movement of people between countries and with expanding live animal exports from endemic regions such as northern Australia, emergence of new foci of melioidosis may well occur in addition to the diagnosis of imported cases in hospitals around the world in people returning from or travelling in endemic regions.
How does infection occur?
In most endemic regions there is a close association between rainfall and melioidosis. In north-east Thailand 60 and northern Australia 61, 75 and 85% of cases, respectively, occur in the wet season. Although the earliest animal studies had shown infection with B. pseudomallei through oral or nasal exposure and from ingestion, recent reviews consider that the majority of human cases are from percutaneous inoculation of B. pseudomallei following exposure to muddy soils or surface water in endemic locations 4, 14, 44. Ingestion 44 and sexual transmission 62 have been suggested as unusual modes of transmission of B. pseudomallei.
Presentations with melioidosis pneumonia following presumptive inoculating skin injuries have been documented in patients with soil-contaminated burns 63 and are common in tropical Australia 44, 61. An animal model has also shown spread of B. pseudomallei to the lungs following burn inoculation 63. This suggests haematogenous spread to the lung rather than inhalation or spread from the upper respiratory tract. This is analogous to post-primary tuberculosis, with disease from haematogenous spread localising in the upper lung zones. Support for this comes from the observation that septicaemic melioidosis pneumonia cases are often more systemically ill than suggested by initial chest radiography 44.
However, it is likely that under certain epidemiological conditions inhalation is the main mode of infection. This was suggested for soldiers exposed to dusts raised by helicopter rotor blades in Vietnam 64. Melioidosis following near drowning is well documented, with the probable infecting event being aspiration 31, 65, 66. Recently, it has been shown that intensity of rainfall is an independent predictor of melioidosis presenting as pneumonia and of a fatal outcome (B.J. Currie, unpublished data). It was postulated that this might be explained by heavy monsoon rainfall and winds resulting in a shift towards inhalation as the mode of infection with B. pseudomallei. The occurrence of a more fulminant disease with a high mortality when inhalation is the mode of infection rather than percutaneous inoculation is analogous to inhalational anthrax and plague 67, 68.
The natural history of infection with Burkholderia pseudomallei
Serology studies indicate that most infection with B.pseudomallei is asymptomatic 45, 69–71. In north-east Thailand, a majority of the rural population is seropositive by indirect haemagglutination (IHA) 60, with most seroconversion occurring between 6 months and 4 yrs of age 71. Although melioidosis occurs in all age groups, severe clinical disease, such as septicaemic pneumonia, is seen mostly in those with risk factors such as diabetes, renal disease and alcoholism 4, 46, 60, 61. In addition to infection by inhalation, bacterial load on exposure (inoculating dose) and virulence of the infecting strain of B. pseudomallei are also likely to influence severity of disease. However, it has been noted that, despite the large bacterial load in severely ill patients with septicaemic pulmonary melioidosis, person-to-person transmission is extremely unusual 9, 72. This, together with the rarity of fulminant melioidosis in healthy people, supports the primary importance of host risk factors for the development of melioidosis.
To date there is no definitive evidence for development ofimmunity from melioidosis with natural exposure to B.pseudomallei and re-infection has occurred with a different strain of B. pseudomallei following successful treatment of melioidosis 73, 74.
The incubation period for melioidosis is likely to be influenced by inoculating dose, mode of infection, host risk factors and differential virulence of infecting B. pseudomallei isolates 64, 75. Rapid onset of melioidosis (even within 24 h of inoculation) has been seen in presumed aspiration following near drowning 31, 65, as well as in a small number of patients with heavy environmental exposure 59. In 25 cases where a clear incubation period could be determined between the inoculating injury and the onset of symptoms, the incubation period was 1–21 days (mean 9 days) 59. This is consistent with a series of nosocomial melioidosis cases from Thailand, where the incubation period was 3–16 days (mean 9.5 days) 76.
Melioidosis presentations can be acute or chronic disease 59. Chronic disease is defined as illness with symptoms for >2 months duration on presentation. Of 252 cases of culture-confirmed melioidosis, 222 (88%) presented with acute illness and 30 (12%) with chronic illness, with no fatalities in the latter group 59.
It has long been recognised that, analogous to tuberculosis, B. pseudomallei has the potential for re-activation, hence, the concern of the Vietnamese time bomb in returned soldiers (see above). Latent periods from exposure to B. pseudomallei in an endemic region to onset of melioidosis in a nonendemic region have been documented to be as long as 29 yrs 56. However, documented cases of re-activated B. pseudomallei are very uncommon. The small numbers of such cases in the USA in comparison to the estimated 225,000 seropositive soldiers who returned from Vietnam 53, 54, suggest re-activation of B. pseudomallei is an infrequent event.
Most cases of melioidosis in endemic areas are recent infections presenting with acute illness 15, 17, 44–46. In the Darwin study, only 3% (8 out of 252) of cases were considered to be re-activation of B. pseudomallei from a latent focus 59. Most cases of re-activation present as pulmonary melioidosis. This is consistent with the latent focus usually being in the lungs, with B. pseudomallei probably dormant within pulmonary macrophages or other cells. Re-activation of melioidosis has been associated with influenza 55, other bacterial sepsis 77 and development of known melioidosis risk factors such as diabetes. It remains unknown what proportion of asymptomatic seropositive people actually have latent infection with the potential for re-activation.
The pathogenesis of melioidosis
There has been a resurgence of interest in B. pseudomallei and melioidosis pathogenesis in the last decade. Concerns of possible bio-terrorism using the bacteria or its virulence components in genetically engineered constructs 78 and of exposure of military personnel to B. pseudomallei have driven funding for recent work. There are excellent reviews of recent developments and the search for virulence factors and potential vaccines 79–83.
While it is clear from laboratory studies of isolates of B.pseudomallei from animals, humans and the environment that there is differing virulence amongst B. pseudomallei isolates 84–86, the importance of this variation in virulence in determining clinical aspects of melioidosis remains uncertain. Molecular typing showing clonality of isolates in animal and human clusters in Australia has revealed that the same outbreak strain can cause different clinical presentations, with host factors being most important in determining the severity of disease 8, 44, 87. Furthermore, molecular studies both within and between endemic regions are required to ascertain if clinically significant strain variation occurs, both in relation to virulence and tissue or organ specificity.
Immune response and host risk factors for melioidosis
There are important host protective mechanisms against B.pseudomallei in cytokine responses, as well as potentially detrimental ones 88, 89. However, the predominant association with fatal melioidosis is the presence of defined patient risk factors 44, 61. The most important risk factors for melioidosis are diabetes, alcohol excess and renal disease, as summarised in table 1
4, 16, 17, 46, 60, 61, 90, 91.
|
The current author has previously suggested that the predisposition to melioidosis in diabetics, cases of alcohol excess and those with chronic renal disease may reflect their impaired polymorphonuclear leukocyte (PMNL) functions, such as mobilisation, delivery, adherence and ingestion 61. There has been recent support for the role of PMNL in initial host containment of infections with other fast-replicating intracellular bacteria such as Listeria monocytogenes, Salmonella typhimurium and Mycobacterium fortuitum 96. Melioidosis has also been described in chronic granulomatous disease 97. The possible primary role of PMNL function in containing B. pseudomallei led to empirical use of granulocyte colony-stimulating factor (G-CSF) in patients with strictly defined septic shock in the intensive care unit at Royal Darwin Hospital. Uncontrolled data show a significant improvement in survival with G-CSF (see below) 61, 98.
The clinical diversity of melioidosis
The earliest descriptions of melioidosis documented the fulminant end of the clinical spectrum, with abscesses throughout both lungs and in many organs 1, 2. At the other end of the spectrum are asymptomatic infections and localised skin ulcers or abscesses without systemic illness. Inoculating dose of B. pseudomallei, mode of transmission, virulence of the infecting bacterial strain, and host predisposition and underlying risk factors will all influence the clinical presentation and outcome.
Howe et al. 64 classified melioidosis as acute, subacute and chronic, while the Darwin study separated acute and chronic disease 59. In the Darwin study, 46% of cases were bacteraemic and overall mortality was 19% 61, compared with 60% bacteraemia and 44% mortality in Thailand 60, and 52% bacteraemia and 46% mortality in Singapore 27.
Pulmonary melioidosis
Pneumonia is the commonest clinical presentation of melioidosis in all studies with around half of all melioidosis patients presenting with pneumonia 4, 14, 16, 17, 21, 27, 46, 61, 64, 99. The proportion with pneumonia is much higher inthose with chronic disease and those presenting after reactivation from a latent focus. In the Darwin prospective study, pneumonia was the primary diagnosis in 127 out of 252 cases (50%) and an additional 21 cases (8%) developed pneumonia after another primary diagnosis 61.
Acute melioidosis pneumonia has a spectrum from fulminant septic shock (mortality 84% in the Darwin study) to mild undifferentiated pneumonia, which can be acute or subacute in nature, both with little mortality. Septicaemic patients present as acutely unwell with high fevers and prostration andoften little initial cough or pleuritic pain 17, 63. There may also be multiple abscesses in abdominal organs. On chestradiography they often have diffuse nodular infiltrates throughout both lungs, which coalesce, cavitate and progress rapidly, consistent with the caseous necrosis andmultiple metastatic abscess formation seen at autopsy 63, 100, 101. However, some septicaemic pneumonia patients have a more predominant cough with productive sputum, dyspnoea and chest radiography showing discrete but progressive consolidation in one or more lobes (fig. 1) 100–102. Acute pneumonia with upper lobe consolidation in endemic regions warrants consideration of melioidosis (fig. 2). While such upper lobe disease has predominated in some reports 101, 102, lower lobe infiltrates were more common overall in non-septicaemic acute and subacute melioidosis from one study 100. Pleural effusions have generally been uncommon in acute melioidosis 102, but effusions and empyema can still occur, especially with lower lobe disease 100, 101.
|
|
). It can also be remitting and relapsing over many years, but acute deterioration with septicaemia may also occur. Classically upper lobe changes with infiltrates and/or cavitation are seen on chest radiography, being present in 37 out of 39 (95%) chronic cases in one study 103. Initial chest radiography showed cavitary disease with or without infiltrates in 27 out of 39 (69%) and infiltrates in 12 out of 39 (31%) 103. Pleural effusions were present in two out of 39, hilar adenopathy in only one out of 39 and only three out of 39 had bilateral disease. The cavities are usually single and thin walled and rarely contain an air-fluid level 102–104. Computed tomography (CT) scan may show small cavities not evident on chest radiography 104. There are numerous reports of chronic melioidosis being initially misdiagnosed as tuberculosis.
|
Melioidosis and cystic fibrosis
An important recent observation is that B. pseudomallei canboth colonise lungs and cause disease in patients with CF. There have been at least three cases of melioidosis in CF patients returning to Europe from a melioidosis-endemic region 40, 57, 58. The similarity to infection with B. cepacia in CF is of concern, given the association of B. cepacia with more rapid deterioration in lung function 13, 105. Most recently, in a series of four patients with CF infected innorthern Australia, there was suggested transmission of B. pseudomallei between two affected siblings 106. Person-to-person transmission of B. pseudomallei is very unusual andthis, together with the prolonged carriage time of B.pseudomallei seen in some of the CF cases, parallels the specific predilection seen for B. cepacia. Patients with CF travelling to melioidosis-endemic locations should be warned of the risk of melioidosis and this should be considered if they become sick after returning.
A summary of other presentations of melioidosis is given in table 2.
|
Definitive diagnosis of melioidosis requires a positive culture of B. pseudomallei. Melioidosis must be considered in febrile patients in or returning from endemic regions toenable appropriate samples and laboratory awareness. B.pseudomallei readily grows in commercially available blood culture media but it is not unusual for laboratories in nonendemic locations to misidentify the bacteria. Culture from nonsterile sites can be problematic and the likelihood of successful culture is increased if sputum, throat swabs, ulcer/skin lesion swabs and rectal swabs are placed into Ashdown's medium, a gentamicin-containing liquid transport broth that results in selective growth of B. pseudomallei 107. Identification of B. pseudomallei can be made by combining the commercial API 20NE or 20E biochemical kit with a simple screening system involving Gram stain, the oxidase reaction, typical growth characteristics and resistance to certain antibiotics 108, 109. Some commercial identification systems are poor at identifying B. pseudomallei 110. Any confirmed culture of B. pseudomallei should be considered to represent active infection, although the rare possibility of sputum colonisation in people with chronic lung disease such as CF has recently been noted 59, 106.
There are a variety of antigen- and DNA-detection techniques used in endemic regions but these are not yet commercially available 109, 111, 112. IHA and other serological assays are available. In endemic areas their usefulness is limited by high rates of background antibody positivity 60, 112. In acute septicemic melioidosis, IHA is often initially negative, but repeat testing may show seroconversion. A positive IHA in a tourist returning from a melioidosis-endemic region is useful in supporting the possibility of melioidosis, but definitive diagnosis still requires a positive culture.
Antibiotic therapy for melioidosis
B. pseudomallei is characteristically resistant to penicillin, ampicillin, first and second generation cephalosporins, gentamicin, tobramycin, and streptomycin 4, 113, 114. Before 1989, "conventional therapy" for melioidosis consisted of a combination of chloramphenicol, trimethoprim/ sulfamethoxazole (cotrimoxazole), doxycycline and sometimes kanamycin, given for 6 weeks–6 months 4, 115.
Studies subsequently showed B. pseudomallei to be susceptible to various newer ß-lactam antibiotics, especially ceftazidime, imipenem, piperacillin, amoxycillin/clavulanate, ceftriaxone and cefotaxime 116–122. Unlike with "conventional antibiotics", most studies suggested these newer ß-lactam antibiotics to be bactericidal for B. pseudomallei 118, 120.
Initial intensive therapy for melioidosis
The most important therapeutic study for melioidosis was an open-label randomised trial in Thailand comparing ceftazidime (120 mg·kg–1·day–1) with "conventional therapy", which showed that ceftazidime was associated with a 50% lower overall mortality in severe melioidosis 115. Ceftazidime then became the drug of choice for initial intensive therapy for melioidosis. Another study from Thailand showed similar results when ceftazidime was used in combination with cotrimoxazole for initial intensive therapy 123. Whether cotrimoxazole added to ceftazidime is superior to ceftazidime alone is currently being studied in Thailand.
The carbapenems, imipenem and meropenem, have the lowest minimum inhibitory concentrations against B. pseudomallei 118–122, 124. Most recently, high-dose imipenem has been shown in another comparative trial from Thailand to be at least as effective as ceftazidime for severe melioidosis, with no differences in mortality between the groups and fewer treatment failures in those given imipenem 99.
In patients with septic shock, preliminary data suggest addition of G-CSF in addition to state-of-the-art intensive care management may increase survival 61, 98.
The duration of initial intensive therapy should be 10 days 114, with the Darwin study guidelines stating at least 14 days, with a longer time period required if critically ill, or for extensive pulmonary disease, deep seated collections or organ abscesses, osteomyelitis, and septic arthritis and neurological melioidosis 61, 125.
Ceftazidime infusions (6g over 24 h, adult dose) through a peripherally inserted central catheter (PICC line) using an elastomeric infusion device (Baxter, Sydney, Australia) in home therapy have enabled early discharge from hospital 61. The absence of any post-antibiotic effect with ceftazidime allows such a continuous infusion, a theoretical advantage over intermittent dosing 126.
Susequent eradication therapy for melioidosis
Following initial intensive therapy, using ceftazidime, imipenem or meropenem, possibly in combination with cotrimoxazole, subsequent eradication therapy is considered necessary for preventing re-crudescence or later relapse of melioidosis.
Both duration of eradication therapy and the best antibiotics to use remain unclear. Molecular typing of isolates from recurrent melioidosis has confirmed that by far the majority are true relapses from failed eradication, rather than new infection 59, 73, 74, 127, 128.
The most important recent trial of eradication therapy was a comparison of doxycycline alone (the most commonly used eradication regimen in the Darwin study until 1998) versus "conventional" chloramphenicol (first 4 weeks only), cotrimoxazole and doxycycline in combination 129. Relapses were significantly commoner in the doxycycline alone group, resulting in a recommendation that doxycycline should not be used alone as a first-line eradication therapy 129. Similar failures of doxycycline alone as eradication therapy were noted in the Darwin study 59, with some Burkholderia pseudomallei relapse isolates showing acquired doxycycline resistance 130. Since changing to eradication therapy with cotrimoxazole alone in the Darwin study, relapses have been almost exclusively in noncompliant patients 61, consistent with the hypothesis that it is cotrimoxazole which is the critical component in the "conventional" combination therapy. Current trials in Thailand will hopefully ascertain whether it is still beneficial to have combination therapy for the eradication phase of melioidosis treatment or whether cotrimoxazole alone is adequate.
See table 3 for Summary of therapy for melioidosis.
|
Footnotes
Previous articles in this series: No. 1: Tärnvik A, Berglund L. Tularaemia. Eur Respir J 2003; 21: 361–373. No. 2: Mabeza GF, Macfarlane J. Pulmonary actinomycosis. Eur Respir J 2003; 21: 545–551. No. 3: Marrie TJ. Coxiella burnetii pneumonia. Eur Respir J 2003; 21: 713–719. No. 4: Mohsen AH, McKendrick M. Varicella pneumonia in adults. Eur Respir J 2003; 21: 886–891. No 5: Morar R, Feldman C. Pulmonary echinococcosis. Eur Respir J 2003; 21: 1069–1077. 
References
